Completed PHASE2 INTERVENTIONAL 3-arm NCT01082640

Effect of Febuxostat on Renal Function in Patients With Gout and Moderate to Severe Renal Impairment

A Multicenter, Randomized, Double-Blind, Phase 2 Study to Evaluate the Effect of Febuxostat Versus Placebo on Renal Function in Gout Subjects With Hyperuricemia and Moderate to Severe Renal Impairment

Sponsor: Takeda

Conditions Renal Impairment

Interventions Febuxostat Placebo

Updated 6 times since 2017 Last updated: Sep 23, 2013 Started: Apr 30, 2010 Primary completion: May 31, 2012 Completion: May 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Renal Impairment and is currently completed. Takeda leads this study, which shows 6 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Apr 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Takeda

Data source: Takeda

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anderson, United States , Arvada, United States , Augusta, United States , Baltimore, United States , Bethlehem, United States , Birmingham, United States , Boise, United States , Brandon, United States , Brooklyn Center, United States , Chattanooga, United States and 48 more locations